TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for high risk and advanced cancers, announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately. Fitzgerald, who has served as CFO since July 2018 and also served as a director, will resign from both roles but will continue to provide transition services to the company. The company has appointed John Tattory as interim CFO, also effective immediately.
Tattory brings more than 25 years of financial and operational management and leadership experience across the pharmaceutical, medical device and biotechnology sectors. His career includes positions at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics and Windtree Therapeutics. He currently serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies. His deep industry knowledge and financial expertise are expected to support TransCode during this transition period.
The leadership change comes at a critical time for TransCode Therapeutics, which is focused on developing novel treatments for metastatic cancers. The company’s lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The appointment of an interim CFO with extensive life science experience could help ensure continuity in financial operations as the company continues its clinical development programs.
For investors and industry observers, the transition raises questions about potential shifts in financial strategy or reporting. Fitzgerald’s departure after nearly six years as CFO may signal a new phase for the company, especially as it navigates the complex and costly process of bringing RNA-based cancer therapies to market. Tattory’s background in both large pharmaceutical firms and smaller biotechnology companies, as well as his consulting experience, may bring a fresh perspective to TransCode’s financial management. However, the interim nature of his appointment means the company will likely conduct a search for a permanent CFO, which could introduce further changes in the coming months.
The announcement was made via a press release, which can be viewed in full at https://nnw.fm/8G3ik. TransCode Therapeutics continues to trade on the NASDAQ under the ticker RNAZ, and the latest news and updates relating to the company are available in its newsroom at https://nnw.fm/RNAZ. The company remains focused on advancing its pipeline of immuno-oncology and RNA therapeutics, and the financial leadership transition is not expected to impact its clinical programs, though stakeholders will be watching closely for any strategic adjustments.
